Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 1/20 | 0.67 |
| ▸ | HTR2A | P28223 | 1/20 | 0.67 |
| ▸ | HTR7 | P34969 | 1/20 | 0.67 |
| ▸ | HTR6 | P50406 | 1/20 | 0.67 |
| ▸ | MAPT | P10636 | 10/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.66 |
| ▸ | HTT | P42858 | 4/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 3/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | GAA | P10253 | 1/20 | 0.61 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 3/20 | 0.60 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 1/20 | 0.59 |
| ▸ | USP2 | O75604 | 1/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27918171 | 0.86 | MAPT (0.69) | MAPTSMN1; SMN2HTTMAPK1MEN1 | |
| SCHEMBL631834 | 0.85 | MAPT (0.68) | MAPTSMN1; SMN2HTTMAPK1MEN1 | |
| SCHEMBL5543934 | 0.85 | MAPT (0.68) | MAPTSMN1; SMN2HTTMAPK1MEN1 | |
| SCHEMBL18711281 | 0.83 | MAPT (0.70) | MAPTSMN1; SMN2HTTMAPK1MEN1 | |
| SCHEMBL14452412 | 0.83 | RAB9A (0.67) | MAPTSMN1; SMN2HTTMAPK1MEN1 | |
| SCHEMBL18375965 | 0.82 | RAB9A (0.79) | MAPTSMN1; SMN2HTTMAPK1MEN1 | |
| SCHEMBL3174172 | 0.81 | CHIA (0.69) | HTR1AHTR2AHTR7HTR6MAPT | |
| SCHEMBL268788 | 0.80 | RAB9A (0.67) | MAPTSMN1; SMN2HTTMAPK1MEN1 | |
| SCHEMBL18701803 | 0.80 | MAPT (0.65) | MAPTSMN1; SMN2HTTMAPK1MEN1 | |
| SCHEMBL10144145 | 0.80 | MAPT (1.00) | MAPTSMN1; SMN2HTTMAPK1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2393829-A1 | ACTAGARDINE DERIVATIVES | Novacta Biosystems Limited (GB) | 2011-12-14 | — | — | EP | claimed |
| WO-2010089544-A1 | ACTAGARDINE DERIVATIVES | NOVACTA BIOSYSTEMS LIMITED (GB) | 2010-08-12 | — | — | WO | claimed |
| US-9192569-B2 | Formulations for infusion of type B lantibiotics | NOVACTA BIOSYSTEMS LIMITED (GB) | 2015-11-24 | — | — | US | disclosed |
| US-8729031-B2 | Compounds | NOVACTA BIOSYSTEMS LIMITED (GB) | 2014-05-20 | — | — | US | disclosed |
| EP-2603204-A2 | FORMULATIONS FOR INFUSION OF TYPE B LANTIBIOTICS | Novacta Biosystems Limited (GB) | 2013-06-19 | — | — | EP | disclosed |
| US-20130137630-A1 | FORMULATIONS FOR INFUSION OF TYPE B LANTIBIOTICS | NOVACTA BIOSYSTEMS LIMITED (GB) | 2013-05-30 | — | — | US | disclosed |
| WO-2012020219-A2 | FORMULATIONS FOR INFUSION OF TYPE B LANTIBIOTICS | NOVACTA BIOSYSTEMS LIMITED (GB) | 2012-02-16 | — | — | WO | disclosed |
| EP-2393829-A1 | ACTAGARDINE DERIVATIVES | Novacta Biosystems Limited (GB) | 2011-12-14 | — | — | EP | disclosed |
| US-20110294723-A1 | Compounds | NOVACTA BIOSYSTEMS LIMITED (GB) | 2011-12-01 | — | — | US | disclosed |
| WO-2010089544-A1 | ACTAGARDINE DERIVATIVES | NOVACTA BIOSYSTEMS LIMITED (GB) | 2010-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130137630-A1 | FORMULATIONS FOR INFUSION OF TYPE B LANTIBIOTICS | SLC5A2, SLC5A11, SPTSSB | HTR1A 4520/4885HTR2A 3288/4885HTR7 3738/4885 |
| US-20110294723-A1 | Compounds | SLC11A2, SDHA, SDHB | HTR1A 4581/4885HTR2A 4018/4885HTR7 3765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.